Meeting
2015 ASCO Annual Meeting
SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.
Authors
Melissa Amber Burgess
University of Pittsburgh Physicians, Pittsburgh, PA
Melissa Amber Burgess , John Crowley , Denise K. Reinke , Richard F. Riedel , Suzanne George , Sujana Movva , Brian Andrew Van Tine , Lara Emily Davis , Scott Schuetze , James Hu , Steven Attia , Dennis A. Priebat , Damon R. Reed , Sandra P. D'Angelo , Scott H. Okuno , Robert G. Maki , Shreyaskumar Patel , Laurence H. Baker , Hussein Abdul-Hassan Tawbi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT02301039
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS10578)
DOI
10.1200/jco.2015.33.15_suppl.tps10578
Abstract #
TPS10578
Poster Bd #
220b
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy.
First Author: Saveri Bhattacharya
Poster
2023 ASCO Annual Meeting
Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients.
First Author: Prantesh Jain
Poster
2021 ASCO Annual Meeting
A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
First Author: Nikhil Shukla
Poster
2021 Gastrointestinal Cancers Symposium
Response to PD-1 and PD-L1 based immunotherapy in MSS advanced colorectal cancer is impacted by metastatic disease sites.
First Author: Marwan Fakih